Both in Diagnostics
Intellia Therapeutics vs Immucell
Over the past year NTLA returned −23.9% and ICCC returned +64.1%; their daily moves had a correlation of 0.06.
NTLA −23.9% ICCC +64.1%Growth of $1, one year, split-adjusted
| Metric | NTLA | ICCC |
|---|---|---|
| Price | $11.26 | $10.24 |
| Market cap | $1.58B | $93.0M |
| Today | +0.45% | −0.10% |
| 1 month | −4.2% | +3.2% |
| 6 months | −13.7% | +24.1% |
| Year to date | +25.3% | +66.5% |
| 1 year | −56.5% | +69.0% |
| Revenue growth (YoY) | −46.2% | +11.5% |
| Gross margin | 100.0% | 33.9% |
| Net margin | −1392.3% | 25.5% |
| P/E (TTM) | — | 118.1× |
| Price / sales | 26.5× | 3.0× |
| Net cash | $437.8M | $557.3K |
| Dividend yield | — | — |
| Volatility (60d) | 57.4% | 37.2% |
| Short % of float | 38.6% | 0.3% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).